AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02480426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CO2 portograms guidance
Description: TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
Study NCT03420768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Administered by intravenous (IV) infusion
Study NCT03474276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azythromycin
Description: Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
Study NCT03474276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inuline and fructo-oligosaccharides
Description: Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
Study NCT03474276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Administration of Albendazole at inclusion of the child : 200mgs, one administration
Study NCT03474276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified blend flour
Description: Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g
Study NCT02288130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa
Study NCT02288130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Study NCT01183351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
Study NCT01771666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan blue
Description: 3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%.
Study NCT01771666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99technetium-sulfur colloid radiolabel
Study NCT01281813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive darunavir (per parent study) as oral suspension.
Study NCT01281813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive ritonavir (per parent study) as oral solution/suspension.
Study NCT02302287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketoacids diet
Description: Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
Study NCT02302287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
Study NCT02302287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free diet
Description: Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
Study NCT02302287 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Free diet
Description: Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
Study NCT04768153 — intervention group
Intervention type: BIOLOGICAL
Intervention: Serology
Description: Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
Study NCT00995787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
Study NCT00970307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2202083A vaccine
Description: Intramuscular, three doses
Study NCT00970307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal vaccine (GSK 1024850A)
Description: Intramuscular, three doses
Study NCT00970307 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-valent pneumococcal vaccine (GSK 1024850A)
Description: Intramuscular, three doses
Study NCT00480922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Description: Outpatient behavioral counseling
Study NCT00970307 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, three doses
Study NCT00480922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: Outpatient behavioral counseling
Study NCT01506752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: improved orally disintegrating E2020 10 mg tablet without water.
Study NCT01506752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: current orally disintegrating E2020 10 mg tablet without water.
Study NCT01506752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: improved orally disintegrating E2020 10 mg tablet with water.
Study NCT00970307 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate®
Description: Intramuscular, two doses
Study NCT00995787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
Study NCT03028701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide 12/400 mcg Discair
Description: Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
Study NCT01895192 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of sperm morphology (contrast microscopy).
Description: Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
Study NCT03497377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Study NCT03497377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-NaF
Study NCT03606577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
Study NCT03606577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
Study NCT01506752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: current orally disintegrating E2020 10 mg tablet with water
Study NCT00547599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
Study NCT04538885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The pleiotropic factor derived from mesenchymal stem cells
Description: The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
Study NCT03768830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise program includes breathing and upper and lower limbs exercise.
Study NCT02497872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biliary stone removal
Description: Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
Study NCT02497872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stone removal
Description: Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
Study NCT02021448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)
Description: Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
Study NCT03237988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Capsules
Description: 100mg Capsule
Study NCT03237988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPI-444 Tablets
Description: 100mg Tablets
Study NCT04519671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
Study NCT04519671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT03606577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
Study NCT03606577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
Study NCT02694978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Study NCT01996904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic repair
Description: If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
Study NCT01996904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic debridement
Description: Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
Study NCT02144454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saturated fat
Study NCT02144454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat
Study NCT02144454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fat
Study NCT03694028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limb Loading
Description: Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
Study NCT03420768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) infusion
Study NCT03694028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
Study NCT02857972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wondaleaf®
Description: Use of Wondaleaf® during menstruation every night in one menstrual cycle.
Study NCT00707564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon Dental Dressing
Description: The HemCon Dental Dressing is an oral wound dressing made of chitosan
Study NCT00707564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze with pressure
Description: Gauze with pressure
Study NCT02694978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCM
Study NCT02737592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trojan Simply Pleasure Personal Lubricant
Description: silicone base without sensate
Study NCT00682617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Description: Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
Study NCT01752049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical timolol maleate
Description: * Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient
Study NCT01752049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline drops
Description: Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
Study NCT02769793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa dispersible
Description: Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Study NCT02769793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Study NCT02229617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous testosterone
Study NCT00678704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 10 mg tablet prior to intercourse on demand
Study NCT00678704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 20 mg tablet prior to intercourse on demand
Study NCT00678704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet prior to intercourse on demand
Study NCT03377751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional posterior wall isolation
Description: PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA).
Study NCT03377751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voltage-guided substrate homogenization
Description: PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA).
Study NCT03377751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI only group
Description: PVI will be performed in this arm.
Study NCT00025415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00025415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02150161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/ ketamine
Study NCT02150161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT02646410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FPD+NDOT
Study NCT02646410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FPD+DOT
Study NCT02646410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DDD+NDOT
Description: Door to door delivery + non directly observed treatment
Study NCT02646410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DDD+DOT
Description: Door to door delivery + directly observed treatment
Study NCT02018211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: passive recovery following exercise test
Study NCT02018211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: graduated compression socks
Description: graduated compression socks worn after test exercise
Study NCT02018211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation device
Description: neuromuscular electrical stimulation device worn after test exercise
Study NCT02998190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Doses of EB8018
Study NCT02998190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Ascending Doses of placebo
Study NCT02998190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Doses of EB8018
Study NCT02998190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple Ascending Doses of placebo
Study NCT00030264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
Study NCT00030264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
Study NCT01280942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWS Nursing Alerts
Description: An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.